Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720304 · OUTCOME

Number of Participants With Acute Grade III/IV Treatment-related Toxicities

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck · Source last updated 2024-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
evaluated every 2 weeks, up to 3 years

What was measured

Number of participants with acute grade III/IV treatment-related toxicities

Analysis population: Participants enrolled in study

Groups in this outcome

Lymphopenia

Lymphopenia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Neutropenia

Neutropenia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Anemia

Anemia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Oral Mucositis

Oral mucositis Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Radiation Dermatitis

Radiation dermatitis Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Acneiform Skin Rash

Acneiform skin rash Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Dysphagia

Dysphagia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Anorexia

Anorexia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Nausia/Vomiting

Nausia/vomiting Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Dehydration

Dehydration Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lymphopenia43
Neutropenia43
Anemia43
Oral Mucositis43
Radiation Dermatitis43
Acneiform Skin Rash43
Dysphagia43
Anorexia43
Nausia/Vomiting43
Dehydration43

Reported measurements

Grade 3
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Lymphopenia24Not reportedNot reportedNot reportedNot reported
Neutropenia2Not reportedNot reportedNot reportedNot reported
Anemia3Not reportedNot reportedNot reportedNot reported
Oral Mucositis14Not reportedNot reportedNot reportedNot reported
Radiation Dermatitis15Not reportedNot reportedNot reportedNot reported
Acneiform Skin Rash4Not reportedNot reportedNot reportedNot reported
Dysphagia20Not reportedNot reportedNot reportedNot reported
Anorexia13Not reportedNot reportedNot reportedNot reported
Nausia/Vomiting7Not reportedNot reportedNot reportedNot reported
Dehydration2Not reportedNot reportedNot reportedNot reported
grade 4
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Lymphopenia17Not reportedNot reportedNot reportedNot reported
Neutropenia0Not reportedNot reportedNot reportedNot reported
Anemia0Not reportedNot reportedNot reportedNot reported
Oral Mucositis1Not reportedNot reportedNot reportedNot reported
Radiation Dermatitis1Not reportedNot reportedNot reportedNot reported
Acneiform Skin Rash0Not reportedNot reportedNot reportedNot reported
Dysphagia1Not reportedNot reportedNot reportedNot reported
Anorexia0Not reportedNot reportedNot reportedNot reported
Nausia/Vomiting0Not reportedNot reportedNot reportedNot reported
Dehydration0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        24
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        3
      4. group Id
        OG003
        value
        14
      5. group Id
        OG004
        value
        15
      6. group Id
        OG005
        value
        4
      7. group Id
        OG006
        value
        20
      8. group Id
        OG007
        value
        13
      9. group Id
        OG008
        value
        7
      10. group Id
        OG009
        value
        2
    title
    Grade 3
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        17
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        1
      5. group Id
        OG004
        value
        1
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        1
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        0
      10. group Id
        OG009
        value
        0
    title
    grade 4
denoms
  1. counts
    1. group Id
      OG000
      value
      43
    2. group Id
      OG001
      value
      43
    3. group Id
      OG002
      value
      43
    4. group Id
      OG003
      value
      43
    5. group Id
      OG004
      value
      43
    6. group Id
      OG005
      value
      43
    7. group Id
      OG006
      value
      43
    8. group Id
      OG007
      value
      43
    9. group Id
      OG008
      value
      43
    10. group Id
      OG009
      value
      43
    units
    Participants
description
Number of participants with acute grade III/IV treatment-related toxicities
groups
  1. description
    Lymphopenia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG000
    title
    Lymphopenia
  2. description
    Neutropenia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG001
    title
    Neutropenia
  3. description
    Anemia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG002
    title
    Anemia
  4. description
    Oral mucositis Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG003
    title
    Oral Mucositis
  5. description
    Radiation dermatitis Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG004
    title
    Radiation Dermatitis
  6. description
    Acneiform skin rash Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG005
    title
    Acneiform Skin Rash
  7. description
    Dysphagia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG006
    title
    Dysphagia
  8. description
    Anorexia Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG007
    title
    Anorexia
  9. description
    Nausia/vomiting Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG008
    title
    Nausia/Vomiting
  10. description
    Dehydration Participant intervention: docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG009
    title
    Dehydration
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants enrolled in study
reporting Status
POSTED
time Frame
evaluated every 2 weeks, up to 3 years
title
Number of Participants With Acute Grade III/IV Treatment-related Toxicities
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice